According to the global COPD market research was estimated to be assets of $11.3 billion and, the prediction to scope a value of $15.6 billion by 2019. Rapid growth of the pulmonary disease will be driven by a great number of new, more suitable and effectual yields entering the market and imposing greater value compared to the remedies that are already available in the market. Daily once LABA/LAMA, fixed-dose combinations of drugs (QVA-149) are now driving the growth of this disease.
Androniki Naska